Fluoroquinolone-Resistant S. Pneumoniae Emerging
In South African children with multidrug-resistant tuberculosis, treatment with fluoroquinolones may have led to the emergence of invasive pneumococcal disease caused by fluoroquinolone-resistant Streptococcus pneumoniae, according the results of a study published online March 24 in The Lancet.
<p>MONDAY, March 24 (HealthDay News) -- In South African children with multidrug-resistant tuberculosis, treatment with fluoroquinolones may have led to the emergence of invasive pneumococcal disease caused by fluoroquinolone-resistant <i>Streptococcus pneumoniae</i>, according the results of a study published online March 24 in <i>The Lancet</i>.</p><p>Between 2000 and 2006, Anne von Gottberg, of the National Institute for Communicable Diseases of the National Health Laboratory Service in Johannesburg, South Africa, and colleagues identified 21,521 patients with invasive pneumococcal disease, and screened isolates from 19,404 of them for ofloxacin resistance. They defined resistance to levofloxacin as a minimum inhibitory concentration of 4 mg/L or more.</p><p>The researchers found that 22 isolates were resistant to ofloxacin, 12 of which contained <i>S. pneumoniae</i> resistant to levofloxacin. All 12 cases of invasive pneumococcal disease resistant to levofloxacin occurred in children under age 15. The investigators also found that invasive disease caused by levofloxacin-resistant <i>S. pneumoniae</i> was associated with a previous history of tuberculosis treatment.</p><p>"Thirty years ago, the first multidrug-resistant pneumococci emerged in a limited, nosocomial setting in South Africa very similar to that described here," the authors write. "Now, multidrug-resistant pneumococci have spread worldwide. Interventions and changes in health policy are required to prevent the uncontrolled spread of levofloxacin resistance among pneumococci."</p><p>Two of the study authors have received research funds from Wyeth.</p><p><a href="http://www.thelancet.com/journals/lancet/article/PIIS0140673608603505/abstract?isEOP=true" target="_new">Abstract</a><br/><a href="http://www.thelancet.com/journals/lancet/article/PIIS0140673608603505/fulltext?isEOP=true" target="_new">Full Text (subscription or payment may be required)</a></p>
Copyright © 2008 <a href="http://www.physiciansbriefing.com/" target="_new">ScoutNews, LLC</a>. All rights reserved.
Pz-cel granted FDA Priority Review to treat recessive dystrophic epidermolysis bullosa
November 28th 2023The FDA granted Priority Review to pz-cel following a phase 1/2 and a pivotal phase 3 study in which the treatment for recessive dystrophic epidermolysis bullosa (RDEB) demonstrated wound healing and pain reduction.
Worsening severity of AD in children associated with increased comorbidity onset risk
November 27th 2023Of patients in the atopic dermatitis (AD) cohort, 36.6% developed at least 1 comorbidity amid follow-up compared to 28.5% in the non-AD reference cohort, investigators of a Sweden, nationwide, population-based cohort study found.
